Cancer Chemical Biology and Metabolism Training Program

项目概要/摘要 丹纳法伯癌症研究所 (DFCI) 的教员正在申请资金来支持一个新的、综合性的、 癌症化学生物学和代谢（CCBM）博士后培训项目——两个协同和 以小分子化学和生物化学为基础的概念上相关的研究学科 从基础研究和转化研究的角度来看，其重要性日益增加。该计划的目标是： 1) 提供与癌症化学生物学和代谢相关的广泛主题的培训，例如 临床前癌症靶标验证、化学筛选、基于结构的药物发现、肿瘤代谢、 肿瘤与宿主代谢之间的串扰、细胞生物能量学和代谢组学、机制 生物化学、蛋白质组学和化学蛋白质组学以及动物肿瘤模型； 2) 让学员熟悉状态- 化学生物学和代谢科学领域最先进的技术和方法，3）培训研究员识别 重要的问题和方法将推动该领域向前发展并提供转化机会 影响癌症治疗； 4）为学员提供发展和提高资助能力的机会 和科学沟通技巧； 5）通过以下方式指导研究员走向独立的科学职业道路 实施个人发展计划（IDP）、个人博士后指导委员会，以及 为学员提供定制机会，根据他们的情况获得指导和教学经验 职业目标。 CCBM 培训计划每年将支持 8 名博士后研究员，为期 2 年。它将是 由一名董事（Thomas Roberts 博士，联系人 PD/PI）和一名联合董事（Nika Danial 博士，PD/PI）管理， 其中包括来自 DFCI 4 个部门的 26 名导师和 6 名联合导师。该计划的主任和共同 总监将与培训监督委员会 (TOC)、外部顾问委员会 (EAB) 和 由实习生领导的咨询小组由现任和过去的项目研究员组成，他们将帮助确定以下方法： 优化程序。衡量学员满意度、量化结果和评估的其他策略 该方案的有效性将包括对受训者和导师的年度调查，以及退出和 校友访谈。通过最先进的核心设施和技术平台提供机构支持，以及 作为支持 T32 特定培训活动和年度 EAB 会议的资金将显着增强 培训计划。除了提供各种科学和职业发展方面的强有力的培训 技能，该计划的一个关键目标是招募和支持更加多样化的学员群体。为进一步确保 该计划在增强多样性方面的有效性，我们的 EAB 和培训监督委员会包括领导者 在多样性和包容性方面拥有丰富的经验。我们相信综合 CCBM 培训计划将 为研究员做好一系列研究职业的准备，并培训将在该领域蓬勃发展的下一代科学家 21世纪的生物医学劳动力将在癌症研究和治疗方面取得突破。 ！

Project Summary/Abstract The faculty of the Dana-Farber Cancer Institute (DFCI) is requesting funds to support a new, integrative, postdoctoral training program in Cancer Chemical Biology and Metabolism (CCBM) — two synergistic and conceptually related research disciplines grounded in small molecule chemistry and biochemistry that are of growing importance from both basic and translational research perspectives. The goals of this program are to: 1) provide training in a wide range of topics relevant to cancer chemical biology and metabolism such as preclinical cancer target validation, chemical screens, structure-based drug discovery, tumor metabolism, cross-talk between tumor and host metabolism, cellular bioenergetics and metabolomics, mechanistic biochemistry, proteomics and chemoproteomics, and animal tumor modelling; 2) familiarize trainees with state- of-the-art technologies and approaches in chemical biology and metabolic science, 3) train fellows to identify important questions and approaches that will move the field forward and provide translational opportunities to impact cancer treatment; 4) provide trainees with opportunities to develop and enhance their grantsmanship and scientific communication skills; 5) coach fellows on their paths to independent careers in science by implementing Individual Development Plans (IDPs), individual postdoctoral mentoring committees, and customized opportunities for trainees to acquire experience in mentoring and teaching depending on their career goals. The CCBM Training Program will support 8 postdoctoral fellows per year for 2-year appointments. It will be administered by a Director (Dr. Thomas Roberts, Contact PD/PI) and a co-Director (Dr. Nika Danial, PD/PI), and will include 26 mentors and 6 co-mentors from 4 departments at DFCI. The program Director and co- Director will work closely with a Training Oversight Committee (TOC), an External Advisory Board (EAB), and a trainee-led advisory group consisting of current and past program fellows who will help identify ways to optimize the program. Additional strategies to measure trainee satisfaction, quantify outcomes, and evaluate the effectiveness of the program will include annual surveys from trainees and mentors, as well as exit and alumni interviews. Institutional support through state-of-the-art core facilities and technology platforms, as well as funds to support T32-specific training activities and yearly EAB meetings will significantly enhance the training program. In addition to offering robust training in a diverse range of scientific and career development skills, a key goal of the program is to recruit and support a more diverse group of trainees. To further ensure the program's effectiveness in enhancing diversity, our EAB and Training Oversight Committee include leaders with deep experience in diversity and inclusion. We believe the integrative CCBM Training Program will prepare fellows for a range of research careers and train the next generation of scientists who will thrive in the 21st century biomedical workforce that will make breakthroughs in cancer research and treatment. !